DK2965749T3 - Nanopartikelsuspensioner indeholdende carboxyvinylpolymer - Google Patents

Nanopartikelsuspensioner indeholdende carboxyvinylpolymer Download PDF

Info

Publication number
DK2965749T3
DK2965749T3 DK15179323.9T DK15179323T DK2965749T3 DK 2965749 T3 DK2965749 T3 DK 2965749T3 DK 15179323 T DK15179323 T DK 15179323T DK 2965749 T3 DK2965749 T3 DK 2965749T3
Authority
DK
Denmark
Prior art keywords
composition
concentration
nepafenac
compositions
present
Prior art date
Application number
DK15179323.9T
Other languages
English (en)
Inventor
Masood A Chowhan
Malay Ghosh
Wesley Weshin Han
Bahram Asgharian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43425837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2965749(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2965749T3 publication Critical patent/DK2965749T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)

Claims (15)

1. Topisk indgivelig vandig opthalmisk suspensionssammensætning omfattende: en carboxyvinylpolymer i en koncentration på 0,1 til 0,5 vægt/volumen%; en galactomannan i en koncentration på 0,1 til 0,4 vægt/volumen%; borat i en koncentration på 0,4 til 2,0 vægt/volumen%; og en svagt opløselig partikelformet forbindelse, hvilken forbindelse har en opløselighed i vand ved 25°C på 0,001 til 0,1 vægt/volumen%.
2. Sammensætning ifølge krav 1, som yderligere omfatter et pH-justerende middel i en mængde, som er tilstrækkelig til at forårsage, at sammensætningen haren pH på 5,0 til 7,2.
3. Sammensætning ifølge krav 1, som yderligere omfatter et tonicitets-justerende middel i en mængde, som er tilstrækkelig til at forårsage, at sammensætningen haren osmolalitet på 250 til 350 mOsm/kg.
4. Sammensætning ifølge krav 1, hvor den svagt opløselige partikelformede forbindelse er nepafenac i en koncentration på 0,1 til 1,0 vægt/volumen%.
5. Sammensætning ifølge krav 1, hvor den nævnte carboxyvinylpolymer er carbomer i en koncentration på 0,4 vægt/volumen%.
6. Sammensætning ifølge krav 1, som yderligere omfatter et formalingsmiddel i en koncentration på 0,005 til 0,1 vægt/volumen%, hvor formalingsmidlet er valgt blandt tyloxapol, polysorbat 80 og natriumcarboxymethylcellulose, fortrinsvis hvor formalingsmidlet er natriumcarboxymethylcellulose.
7. Sammensætning ifølge krav 1, som yderligere omfatter et metalchloridsalt-tonicitet-justeringsmiddel, fortrinsvis natriumchlorid i en koncentration på 0,4 vægt/volumen%.
8. Sammensætning ifølge krav 1, som yderligere omfatter en ikke-ionisk hydroxyl-forbindelse som et tonicitet-justeringsmiddel.
9. Sammensætning ifølge krav 1, som yderligere omfatter såvel et konserveringsmiddel som en chelatdanner.
10. Sammensætning ifølge krav 9, hvor konserveringsmidlet er benzalkoniumchlorid i en koncentration på 0,005 vægt/volumen% og chelatdanneren er edetatdinatrium i en koncentration på 0,01 vægt/volumen%.
11. Sammensætning ifølge krav 1, hvor carboxyvinylpolymeren er carbomer, galacto-mannanet er guar, boratet er borsyre og den svagt opløselige partikelformede forbindelse er nepafenac i en koncentration på 0,1 til 1,0 vægt/volumen%.
12. Sammensætning ifølge krav 11, omfattende 0,4 vægt/volumen% carbomer, 0,2 vægt/volumen% guar, 0,5 vægt/volumen% borsyre og 0,3 vægt/volumen% nepafenac.
13. Sammensætning ifølge krav 12, hvor det nævnte nepafenac har en gennemsnitlig partikelstørrelse på 400 nm.
14. Sammensætning ifølge krav 1 til anvendelse ved en fremgangsmåde til behandling af ophthalmiske lidelser hos en patient, omfattende topisk indgivelse til patienten af sammensætningen.
15. Fremgangsmåde til opretholdelse af viskositeten for en topisk ophthalmisk sammensætning omfattende 0,1 til 0,5 vægt/volumen% carbomer, når sammensætningen påføres topisk på øjet, hvilken fremgangsmåde omfatter: tilføjelse af galactomannan i tilstrækkelig mængde til tilvejebringelse af en koncentration på 0,1 vægt/volumen% til 0,4 vægt/volumen% galactomannan i sammensætningen, og borat i en tilstrækkelig mængde til tilvejebringelse af en koncentration på 0,4 vægt/volumen% til 0,6 vægt/volumen% i sammensætningen.
DK15179323.9T 2009-12-03 2010-12-01 Nanopartikelsuspensioner indeholdende carboxyvinylpolymer DK2965749T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26636809P 2009-12-03 2009-12-03
EP13152584.2A EP2586426B1 (en) 2009-12-03 2010-12-01 Carboxyvinyl polymer-containing nanoparticle suspensions

Publications (1)

Publication Number Publication Date
DK2965749T3 true DK2965749T3 (da) 2018-08-27

Family

ID=43425837

Family Applications (3)

Application Number Title Priority Date Filing Date
DK15179323.9T DK2965749T3 (da) 2009-12-03 2010-12-01 Nanopartikelsuspensioner indeholdende carboxyvinylpolymer
DK10787650.0T DK2506831T3 (da) 2009-12-03 2010-12-01 Carboxyvinylpolymerholdige nanopartikelsuspensioner
DK13152584.2T DK2586426T3 (da) 2009-12-03 2010-12-01 Carboxyvinylpolymer-holdige nanopartikelsuspensioner

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK10787650.0T DK2506831T3 (da) 2009-12-03 2010-12-01 Carboxyvinylpolymerholdige nanopartikelsuspensioner
DK13152584.2T DK2586426T3 (da) 2009-12-03 2010-12-01 Carboxyvinylpolymer-holdige nanopartikelsuspensioner

Country Status (27)

Country Link
US (3) US8921337B2 (da)
EP (3) EP2506831B1 (da)
JP (3) JP5864433B2 (da)
KR (2) KR101809484B1 (da)
CN (1) CN102724965B (da)
AR (2) AR080572A1 (da)
AU (1) AU2010326099B2 (da)
BR (1) BR112012013503B8 (da)
CA (1) CA2781254C (da)
CL (1) CL2012001402A1 (da)
CY (1) CY1120585T1 (da)
DK (3) DK2965749T3 (da)
ES (3) ES2684752T3 (da)
HR (2) HRP20140016T1 (da)
HU (2) HUE025838T2 (da)
LT (1) LT2965749T (da)
MX (1) MX2012006231A (da)
PH (1) PH12012501111A1 (da)
PL (3) PL2586426T3 (da)
PT (3) PT2506831E (da)
RS (2) RS57465B1 (da)
RU (1) RU2571078C2 (da)
SI (3) SI2506831T1 (da)
TW (1) TWI486178B (da)
UY (1) UY33081A (da)
WO (1) WO2011068872A2 (da)
ZA (1) ZA201203770B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435631B2 (en) * 2010-04-15 2013-05-07 Ppg Industries Ohio, Inc. Microporous material
PT2596072E (pt) * 2010-07-20 2014-09-02 C Ip S A Suspensão de um composto de boro
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
MX2015002208A (es) * 2012-08-31 2015-05-08 Bausch & Lomb Composiciones oftalmicas con acidos grasos omega-3.
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
US20150191647A1 (en) * 2014-01-07 2015-07-09 Trican Well Service Ltd. Stability of viscous fluids in low salinity environments
EP3470059B1 (en) 2015-01-26 2020-04-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
WO2016205574A1 (en) * 2015-06-18 2016-12-22 Common Pharma, Inc Antimicrobial formulations
US11730699B2 (en) 2018-02-21 2023-08-22 Alcon Inc. Lipid-based ophthalmic emulsion
TWI884130B (zh) * 2018-02-21 2025-05-21 瑞士商愛爾康公司 基於脂質的眼用乳劑

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864183A (en) * 1972-11-21 1975-02-04 Tokyo Hat Method for producing pen core from filament tows
US4313949A (en) 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
FR2761959B1 (fr) * 1997-04-15 1999-05-21 Oreal Ensemble de conditionnement et d'application d'un produit fluide
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
IT1306123B1 (it) 1999-04-02 2001-05-30 Technopharma Sa Soluzione oftalmica viscosizzata con azione detergente sulle lenti acontatto.
ITMI991453A1 (it) 1999-07-01 2001-01-01 Farmila Farma Milano Composizioni oftalmiche in forma di gel acquosi
CN1402629A (zh) 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
TNSN03137A1 (en) 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
EP1448209A2 (en) 2001-10-23 2004-08-25 Ranbaxy Laboratories, Ltd. A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
MXPA04008171A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulacion oftalmica con sistema de goma.
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US7947295B2 (en) 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
FR2865648B1 (fr) 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
WO2006062875A1 (en) 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
TWI393567B (zh) 2005-03-31 2013-04-21 Bausch & Lomb 治療乾眼之組合物及相關之製造方法及使用方法
JP4257860B2 (ja) * 2005-04-19 2009-04-22 中得工業株式会社 化粧材の塗布具
BRPI0609227A2 (pt) * 2005-05-10 2010-03-09 Alcon Inc composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos
DK1906916T3 (da) * 2005-05-10 2009-01-19 Alcon Inc Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser
AU2006254825A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
WO2007058935A2 (en) 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20080039398A1 (en) 2006-01-25 2008-02-14 Ousler George W Iii Formulations and methods for treating dry eye
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
US20070254841A1 (en) 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US20070299124A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
WO2008002485A2 (en) 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
WO2008153746A1 (en) 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
BRPI0910717A2 (pt) * 2008-04-26 2015-09-29 Alcon Res Ltd sistema polimérico de lágrima artificial
JP4395189B1 (ja) * 2008-08-29 2010-01-06 株式会社ソリトン 塗布具
EP2393837A1 (en) * 2009-02-05 2011-12-14 Alcon Research, Ltd. Process for purifying guar
JP5716960B2 (ja) * 2011-05-23 2015-05-13 オーベクス株式会社 塗布体用素材の製造方法及び塗布体用素材並びに塗布体及び塗布具

Also Published As

Publication number Publication date
UY33081A (es) 2011-04-29
KR20150063587A (ko) 2015-06-09
KR20120099269A (ko) 2012-09-07
CY1120585T1 (el) 2019-07-10
LT2965749T (lt) 2018-08-10
ZA201203770B (en) 2013-08-28
ES2441420T3 (es) 2014-02-04
JP2013512912A (ja) 2013-04-18
EP2506831B1 (en) 2013-11-20
RU2012127675A (ru) 2014-01-20
SI2965749T1 (sl) 2018-09-28
US20110135743A1 (en) 2011-06-09
HRP20140016T1 (hr) 2014-01-31
WO2011068872A3 (en) 2012-01-12
ES2684752T3 (es) 2018-10-04
EP2965749A1 (en) 2016-01-13
AR122463A2 (es) 2022-09-14
MX2012006231A (es) 2012-07-03
PL2586426T3 (pl) 2016-01-29
TWI486178B (zh) 2015-06-01
PL2506831T3 (pl) 2014-05-30
PT2965749T (pt) 2018-10-09
HUE038821T2 (hu) 2018-11-28
RS53085B (sr) 2014-06-30
WO2011068872A2 (en) 2011-06-09
CN102724965A (zh) 2012-10-10
RU2571078C2 (ru) 2015-12-20
EP2506831A2 (en) 2012-10-10
US20170020818A1 (en) 2017-01-26
AU2010326099B2 (en) 2013-03-07
BR112012013503A2 (pt) 2016-06-07
RS57465B1 (sr) 2018-09-28
HUE025838T2 (en) 2016-04-28
JP6055849B2 (ja) 2016-12-27
CA2781254A1 (en) 2011-06-09
HRP20181337T1 (hr) 2018-10-19
HK1178802A1 (en) 2013-09-19
EP2965749B1 (en) 2018-05-23
BR112012013503B8 (pt) 2021-05-25
ES2550942T3 (es) 2015-11-13
HK1217091A1 (en) 2016-12-23
EP2586426A1 (en) 2013-05-01
DK2586426T3 (da) 2015-11-23
BR112012013503B1 (pt) 2021-04-20
WO2011068872A8 (en) 2013-04-04
PH12012501111A1 (en) 2016-09-09
CN102724965B (zh) 2015-08-05
DK2506831T3 (da) 2013-12-16
AU2010326099A1 (en) 2012-07-19
SI2586426T1 (sl) 2015-11-30
TW201129395A (en) 2011-09-01
EP2586426B1 (en) 2015-09-23
KR101543613B1 (ko) 2015-08-11
PT2506831E (pt) 2014-01-08
CA2781254C (en) 2016-06-28
JP2016106155A (ja) 2016-06-16
AR080572A1 (es) 2012-04-18
US8921337B2 (en) 2014-12-30
JP5864433B2 (ja) 2016-02-17
CL2012001402A1 (es) 2014-03-28
JP2015061886A (ja) 2015-04-02
SI2506831T1 (sl) 2014-01-31
US9662398B2 (en) 2017-05-30
KR101809484B1 (ko) 2017-12-15
HK1170164A1 (en) 2013-02-22
US20150072011A1 (en) 2015-03-12
PT2586426E (pt) 2015-11-17
PL2965749T3 (pl) 2018-10-31

Similar Documents

Publication Publication Date Title
DK2965749T3 (da) Nanopartikelsuspensioner indeholdende carboxyvinylpolymer
US11058684B2 (en) Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
CA2774704A1 (en) Ophthalmic formulation and method of manufacture thereof
HK1217091B (en) Carboxyvinyl polymer-containing nanoparticle suspensions
HK1170164B (en) Carboxyvinyl polymer-containing nanoparticle suspensions
HK1178802B (en) Carboxyvinyl polymer-containing nanoparticle suspensions